Fang-cheng Li

Prof. Fang-cheng Li

Department of Neurosurgery, Guangzhou Women and Children's Medical Center

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
WCWei Chen
Wei Chen
XXXin-Ke Xu
Xin-Ke Xu
JLJun-Liang Li
Jun-Liang Li
KKKuan-Kei Kong
Kuan-Kei Kong
HLHui Li
Hui Li
FLFang-cheng Li
Fang-cheng Li
MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression

1 July 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LLLu Liu
Lu Liu
SYShuyao Yang
Shuyao Yang
KLKefeng Lin
Kefeng Lin
XYXiaoman Yu
Xiaoman Yu
JMJiaqi Meng
Jiaqi Meng
DJdi jin
di jin
Tumor immune microenvironment exerts a profound effect on the population of infiltrating immune cells. Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) is frequently overexpressed in a variety of cells, particularly during inflammation and tissue injury. However, its function in cancer and immunity remains enigmatic. In this study, we find that TIMP1 is substantially up-regulated during tumorigenesis through analyzing cancer bioinformatics databases, which is further confirmed by IHC tissue microarrays of clinical samples. The TIMP1 level is significantly increased in lymphocytes infiltrating the tumors and correlated with cancer progression, particularly in GBM. Notably, we find that the transcriptional factor Sp1 binds to the promoter of TIMP1 and triggers its expression in GBM. Together, our findings suggest that the Sp1-TIMP1 axis can be a potent biomarker for evaluating immune cell infiltration at the tumor sites and therefore, the malignant progression of GBM.

1 July 2020 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
SWShengwen Wang
Shengwen Wang
CCCheng Chen
Cheng Chen
JLJunliang Li
Junliang Li
XXXinke Xu
Xinke Xu
WCWei Chen
Wei Chen
FLFang-cheng Li
Fang-cheng Li

1 April 2017 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
DLDingyuan Luo
Dingyuan Luo
WCWei Chen
Wei Chen
YTYun Tian
Yun Tian
JLJunliang Li
Junliang Li
XXXinke Xu
Xinke Xu
FLFang-cheng Li
Fang-cheng Li
Glioma is the most common and aggressive human primary tumor in the central nervous system. Despite present clinical advancements, median survival time remains poor in this malignant tumor. Serpin peptidase inhibitor, clade A member 3 (SERPINA3), is a member of the serpin superfamily of protease inhibitors. Its aberrant expression has been observed in various tumors. However, its clinical significance and biological function in glioma remain unclear, especially for the prognosis of glioma patients. In this study, we investigated SERPINA3 expression in glioma tissue samples and its significance in predicting the prognosis of glioma patients. SERPINA3 protein expression was studied by immunohistochemistry, while real-time polymerase chain reaction was used to study SERPINA3 mRNA expression. We found that SERPINA3 was upregulated in glioma tissue at both mRNA and protein levels, compared with noncancerous brain tissues. We also found that high SERPINA3 expression in glioma tissues correlated significantly with advanced World Health Organization grade. Univariate and multivariate analyses revealed that high SERPINA3 expression was an independent prognostic factor for poor overall survival of glioma patients. Moreover, our findings were further validated by online Oncomine database. Taken together, our results suggest that SERPINA3 plays an oncogenic role in glioma progression and provide an insight into the application of SERPINA3 as a novel predictor of clinical outcomes and a potential biomarker of glioma.

1 February 2018 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
WCWei Chen
Wei Chen
KKKuan-Kei Kong
Kuan-Kei Kong
XXXin-Ke Xu
Xin-Ke Xu
CCCheng Chen
Cheng Chen
HLHui Li
Hui Li
FLFang-cheng Li
Fang-cheng Li
Glioblastoma (GBM) is the most common type of malignant brain tumor. In spite of recent advancements in surgical techniques, chemotherapy, and radiation therapy, patients with GBM often face a dire prognosis. MicroRNAs have been shown to modulate the aggressiveness of various cancers, and have emerged as possible therapeutic agents for the management of GBM. miR-205 is dysregulated in glioma and act as a prognostic indicator. However, the role of miR-205 in the development of GBM has not been elucidated. To better understand the pathogenesis of GBM, we examine the biological significance and molecular mechanisms of miR-205 in GBM cells. Zinc finger E-box binding homeobox 1 (ZEB1) has been shown to regulate the epithelial-mesenchymal transition (EMT), which is strongly associated with GBM malignancy. In the present study, we show miR-205 expression is reduced in GBM tissues and cell lines, and ZEB1 expression is inversely correlated with miR-205 expression. We also show ZEB1 is a downstream target of miR-205 and the Akt/mTOR signaling pathway is activated when miR-205 interacts with ZEB1. Increased activity of miR-205 in GBM cells significantly inhibits migration and invasion, and prevents EMT. Furthermore, overexpression of ZEB1 partially abolishes these inhibitory effects of miR-205. We show that miR-205 negatively regulates the expression of ZEB1 in GBM, inhibits cell migration and invasion, and prevents EMT, at least in part through the inhibition of the activation of the Akt/mTOR signaling pathway. Our results indicate miR-205 may be an efficacious therapeutic agent in the treatment of GBM.

14 August 2018 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
DLDingyuan Luo
Dingyuan Luo
XXXinke Xu
Xinke Xu
JLJunliang Li
Junliang Li
CCCheng Chen
Cheng Chen
WCWei Chen
Wei Chen
FLFang-cheng Li
Fang-cheng Li
Glioblastoma multiforme (GBM) is the most common primary malignant tumor affecting the human brain. Despite improvements in therapeutic technologies, patients with GBM have a poor clinical result and the molecular mechanisms responsible for the development of GBM have not yet been fully elucidated. 3-phosphoinositide dependent protein kinase 1 (PDK1) is upregulated in various tumors and promotes tumor invasion. In glioma, transforming growth factor-β (TGF‑β) promotes cell invasion; however, whether TGF‑β directly regulates PDK1 protein and promotes proliferation and invasion is not yet clear. In this study, PDK1 levels were measured in glioma tissues using tissue microarray (TMA) by immunohistochemistry (IHC) and RT‑qPCR. Kaplan-Meier analyses were used to calculate the survival rate of patients with glioma. In vitro, U251 and U87 glioma cell lines were used for functional analyses. Cell proliferation and invasion were analyzed using siRNA transfection, MTT assay, RT‑qPCR, western blot analysis, flow cytometry and invasion assay. In vivo, U251 glioma cell xenografts were established. The results revealed that PDK1 protein was significantly upregulated in glioma tissues compared with non-tumorous tissues. Furthermore, the higher PDK1 levels were associated with a large tumor size (>5.0 cm), a higher WHO grade and a shorter survival of patients with GBM. Univariate and multivariate analyses indicated that PDK1 was an independent prognostic factor. In vivo, PDK1 promoted glioma tumor xenograft growth. In vitro, functional analyses confirmed that TGF‑β upregulated PDK1 protein expression and PDK1 promoted cell migration and invasion, and functioned as an oncogene in GBM, by upregulating c‑Jun protein and inducing epithelial-mesenchymal transition (EMT). c‑Jun protein were overexpressed in glioma tissues and positively correlated with PDK1 levels. Moreover, our findings were further validated by the online Oncomine database. On the whole, the findings of this study indicate that in GBM, PDK1 functions as an oncogene, promoting proliferation and invasion.